HomeCompareTHMO vs MAIN

THMO vs MAIN: Dividend Comparison 2026

THMO yields 2000000.00% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THMO wins by $4.879226400974806e+39M in total portfolio value
10 years
THMO
THMO
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full THMO calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — THMO vs MAIN

📍 THMO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHMOMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THMO + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THMO pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THMO
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, THMO beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THMO + MAIN for your $10,000?

THMO: 50%MAIN: 50%
100% MAIN50/50100% THMO
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

THMO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-41.9
Piotroski
3/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THMO buys
0
MAIN buys
0
No recent congressional trades found for THMO or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHMOMAIN
Forward yield2000000.00%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$4.879226400974806e+39M$47.95M
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$40,208,699.11
Total dividends collected$4.879195005460081e+39M$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusBuyHold

Year-by-year: THMO vs MAIN ($10,000, DRIP)

YearTHMO PortfolioTHMO Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$200,010,700$200,000,000.00$12,464$1,223.78+$200.00MTHMO
2$3,738,731,768,458$3,738,517,757,009.35$16,353$2,343.58+$3738731.75MTHMO
3$65,315,062,866,930,490$65,311,062,423,938,240.00$23,105$4,724.42+$65315062866.91MTHMO
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$36,226$10,256.23+$1066400830062625.00MTHMO
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$65,426$24,707.64+$16272182796453826560.00MTHMO
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$142,101$68,562.02+$2.3205424011366188e+23MTHMO
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$388,521$228,799.95+$3.0927990661046884e+27MTHMO
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$1,397,868$961,169.80+$3.8524105697352695e+31MTHMO
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$6,884,663$5,313,459.69+$4.484688260147987e+35MTHMO
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$47,947,060$40,208,699.11+$4.879226400974806e+39MTHMO

THMO vs MAIN: Complete Analysis 2026

THMOStock

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

Full THMO Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this THMO vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THMO vs SCHDTHMO vs JEPITHMO vs OTHMO vs KOTHMO vs ARCCTHMO vs HTGCTHMO vs GBDCTHMO vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.